VX-659 + Tezacaftor + Ivacaftor - A Phase 3 Study of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)
University of Michigan Medical Center 500 S State St,, MI USA
sstrathdee@ucsd.edu.test (718) 908-5604
